Form S-3 AMARIN CORP PLC\UK

Go back to Form S-3 AMARIN CORP PLC\UK

Aegis Capital Comments on Amarin (AMRN) Following Q2 Results, Commercialization Update

August 8, 2014 9:23 AM EDT

Aegis Capital affirms its Buy rating and $2 price target on Amarin (Nasdaq: AMRN) following Q2 results.

Analyst Ram Selvaraju commented, [Amarin] recorded $12.6mm in Vascepa sales, below our estimate of $14mm. R&D expenses were $11.7mm, slightly above our forecast of $10mm, and SG&A expenses were $21.1mm, also above our projection of $18mm. While the firm reported earnings per share of $0.08 vs. our expectation of a... More

Amarin Corp plc (AMRN) Files $300M Mixed Securities Shelf

August 7, 2014 4:22 PM EDT

Amarin Corp plc (NASDAQ: AMRN) filed a $300 million mixed securities shelf on form S-3.

... More